Mountain View, CA – December 5, 2008 – REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, will present preclinical data on the company’s potential therapeutic treatment for Graft versus Host Disease (GvHD) at the American Society of Hematology Annual Meeting (ASH) being held December 6 through 9 in San Francisco, California. REGiMMUNE is developing KRN7000 (RGI-2001) as a new immunosuppressant for GvHD associated with stem cell transplantation. Two posters will be presented at ASH on the evenings of Sunday December 7 and Monday December 8, respectively.

Abstract/Poster II-426
Sunday, December 7: 6:00 PM – 8:00 PM

Donor-Specific Tolerance Induction through Expansion of DCregs and Tregs by a Liposomal Formulation of KRN7000 (RGI-2001)

Abstract/Poster III-582
Monday, December 8: 5:30 PM – 7:30 PM

A Liposomal Formulation of KRN7000 (RGI-2001) Potently Reduces GvHD Lethality through the Expansion of CD4+Foxp3+ Regulatory T cells in Murine Models.

“We are delighted to present our progress on RGI-2001 development at the 50th ASH Annual Meeting,” said Mr. Haru Morita, President and Chief Executive Officer, REGiMMUNE. “This is a great opportunity to provide an update on our pre-IND stage product candidate, RGI-2001, which is in a preclinical study for GvHD associated with bone marrow transplantation. The company is also developing RGI-2001 for solid organ transplantation. Our mission is to develop novel therapies for immune disorders including allergies, autoimmune diseases and transplantation. We believe the success of RGI-2001 will be the first demonstration of the promise of our proprietary technology and of the company’s significant development capabilities.”

About REGiMMUNE
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and inflammatory disorders. In addition to its potential for GvHD, ToleroVax is a therapeutic candidate for autoimmune diseases such as Multiple Sclerosis (MS) and Systemic Lupus, in which down-regulation of and/or dysfunction of regulatory T-cells lead to serious up-regulation of immunity against the auto-antigen. reVax is the company’s second proprietary technology platform, which works by modulating the immune system by enhancing antigen-specific immune regulatory cells. This technique is expected to be useful in conditions such as Ragweed Allergy, Rheumatoid Arthritis and MS, where control of an abnormal immune response is desirable. reVax is being utilized to advance several compounds through clinical development and eventual commercialization of a broad range of products for REGiMMUNE and its partners. The company is headquartered in Tokyo, Japan and has a U.S. subsidiary in Mountain View, California.. For more information, visit ja.regimmune.com.

About the ASH Annual Meeting
Held annually in December, the Society’s annual meeting provides hematologists from around the world a forum for discussing critical issues in hematology. More than 21,000 clinicians, scientists, and others attend the four-day meeting, which consists of a superb educational program and cutting-edge scientific sessions. The annual meeting features oral and poster presentations that are chosen by peer-reviewers from abstracts submitted prior to the meeting and contain the latest and most exciting developments in scientific research. Plenary symposia and named lectures on specialized areas of hematology are also presented throughout the meeting program.

US MEDIA CONTACT: Debra Bannister
530 676-8001